NEFL and myeloid sarcoma: Currently, there is large heterogeneity on optimal values to establish what is pathological, to estimate the risk of conversion from RIS/CIS to clinically definite MS, to accurately predict disease progression, and to determine adequate treatment response (i.e., what would be considered a significant drop in NfL to reflect treatment response).